clinical trial · NCT05625399
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
Bristol-Myers Squibb·phase3·active not recruiting·n = 579
MelanomaNivolumab + RelatlimabrHuPH20
brief summary
The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma.
started
Mar 6, 2023
primary completion
Aug 4, 2025
completion
Nov 18, 2027
last updated
Jun 3, 2026
official title
A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination Versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants With Previously Untreated Metastatic or Unresectable Melanoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol